Status:
COMPLETED
Assay for the Pancreatic Polypeptide: an Help for Clinical Practice Guidelines in Classification of the Diabetes
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Cochin Hospital's Hormonology Laboratory
Conditions:
Type1diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate global endocrine function within type 1 and type 3c diabetic patients, helping pancreatic polypeptide measurement.
Detailed Description
All diabetes are the result of endrocrine deficiency. The endocrine deficiency may be absolute, as in type 1 diabetes, considered as an elective and exclusive attack of pancreatic Beta cell, or it cou...
Eligibility Criteria
Inclusion
- Patients aged 18 years or older
- Patients with type 1 diabetes with anti-GAD and / or IA2 and / or Znt8 positive antibodies, or characteristic clinical history, with and without exocrine deficiency (\*)
- Patients with chronic alcoholic pancreatitis or cystic fibrosis origin (type 3c diabetes), complicated with diabetes defined by HbA1c\> 6.5% or treated with oral anti-diabetic and / or insulin
- Patients who have given informed and written consent to participate in research
- Patients affiliated to a social security scheme (\*): The exocrine deficiency is defined by an assay of fecal elastase:
- without deficit of exocrine function = fecal elastase = /\> 100 μg / g
- with deficit of exocrine function = fecal elastase \<100 μg / g
Exclusion
- Pregnancy
- Severe renal impairment (eDFG \<45 mL / min / 1.73 m²)
Key Trial Info
Start Date :
June 14 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 18 2019
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT03396146
Start Date
June 14 2018
End Date
December 18 2019
Last Update
April 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cochin Hospital
Paris, France, 75014